Benign prostat hiperplazisinde kombinasyon tedavileri

Ali ATAN (Gazi Üniversitesi, Tıp Fakültesi, Üroloji Anabilim Dalı, Ankara, Türkiye)
Androloji Bülteni
5 2
Yıl: 2021 Cilt: 23 Sayı: 1 Sayfa Aralığı: 30 - 36 Metin Dili: Türkçe DOI: 10.24898/tandro.2021.05945 İndeks Tarihi: 14-05-2021

Benign prostat hiperplazisinde kombinasyon tedavileri

Öz:
BPH medikal tedavisinde tek ilaç tedavisinin başarısız olduğu durum-larda kombinasyon tedavileri kullanılmaktadır. Bu amaçla kullanılan çeşitli kombinasyonlar klinik pratiğimize girmiştir. Her hastanın klinik bulgularına ve beklentilerine uygun olan bir kombinasyon tedavisi seçi-lebilir. Bu derlemede mecvut kombinasyon tedavilerinin endikasyonları ve faydaları ile ilgili güncel veriler sunulacaktır.
Anahtar Kelime:

Combination treatments in benign prostatic hyperplasia

Öz:
Combination therapies are used when single drug therapy fails in BPH medical treatment. Various combinations used for this purpose have entered our clinical practice. A combination therapy appropriate to the clinical findings and expectations of each patient can be selected. In this review, current data on the indications and benefits of these combinations will be presented.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1.Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 1995;22:285–90. https://pubmed.ncbi.nlm.nih.gov/7539174/
  • 2.Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl 1989;2:69–77. [CrossRef ]
  • 3.D’Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 2019;38:433–77. [CrossRef ]
  • 4.Lepor H. Nonoperative management of benign prostatic hyperplasia. J Urol 1989;141:1283–89. [CrossRef ]
  • 5.Roosen A, Chapple CR, Dmochowski RR, Fowler CJ, Gratzke C, Roehrborn CG, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol 2009;56:810–20. [CrossRef ]
  • 6.Fullhase C, Chapple C, Cornu JN, Nunzio CD, Gratzke C, Kaplan SA, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228–43. [CrossRef ]
  • 7.Govorov A, Kasyan G, Priymak D, Pushkar D, Sorsaburu S. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Cent European J Urol 2014;67:167–77. [CrossRef ]
  • 8.Fullhasse C, Schneider MP 5-Alpha-Reductase inhibitors and combination therapy. Urol Clin North Am 2016;43:325–36. [CrossRef ]
  • 9.Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533–9. [CrossRef ]
  • 10.Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, et al. Sustained release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34:169–75. [CrossRef ]
  • 11.Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119–26. [CrossRef ]
  • 12.McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98. [CrossRef ]
  • 13.Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia:4-year results from the CombAT study. Eur Urol 2010;57:123–31. [CrossRef ]
  • 14.Roehrborn CG, Oyarzabal PI, Calomfirescu N, Brotherton B, Wang F, Palacios JM, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia:2-year CONDUCT study results. BJU Int 2015;116:450–59. [CrossRef ]
  • 15.Ong HL, Liao CH, Kuo HC. Long-term combination therapy with α-blockers and 5α-reductase inhibitors in benign prostatic hyperplasia: patient adherence and causes of withdrawal from medication. Int Neurourol J 2016;20:356–62. [CrossRef ]
  • 16.Haque N, Masumori N, Sakamoto S, Ye Z, Yoon SJ, Kuo HC, et al. Superiority of dutasteride 0 5 mg and tamsulosin 0 2 mg for the treatment of moderate‐to‐severe benign prostatic hyperplasia in Asian men. Int J Urol 2018;25:944–51. [CrossRef ]
  • 17.Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB; SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol, 2003 44:461–6. [CrossRef ]
  • 18.Nickel JC, Barkin J, Koch C, Dupont C, Elhilali M. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2008;2:16–21. [CrossRef ]
  • 19.McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). The American Urological Association. https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)
  • 20.Gravas S, Bach T, Bachmann A, Gratzke, Herrmann TRW, Mamoulakis C, et al. Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urolog, 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5
  • 21.Nickel J, Gilling P, Tammela T, Morrill B, Wilson T, Rittmaster R. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388–94. [CrossRef ]
  • 22.Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–14. [CrossRef ]
  • 23.Dmochowski R. Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep 2006;7:462–67. [CrossRef ]
  • 24.Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Wiao H, Zhang X. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007;120:370–4. [CrossRef ]
  • 25.Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive blad der: A randomized controlled trial. JAMA 2006;296:2319–28. [CrossRef ]
  • 26.Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol 2013;190:2153–60. [CrossRef ]
  • 27.Hao N, Tian Y, Liu W, Wang J, Liu L, Wang K, Hong Li. Antimuscarinics and alpha-blockers or alphablockers monotherapy on lower urinary tract symptoms: a meta-analysis. Urology 2014;83:556–62. [CrossRef ]
  • 28.Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo SW, et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: Updated Meta-Analysis. PLoS One 2017;12: e0169248. [CrossRef ]
  • 29.Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Gotoh M. Long-term efficacy of a combination therapy with an anticholinergic agent and an alpha1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn 2017;36:748–54. [CrossRef ]
  • 30.Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholiner-gic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 2003;326:841–4. [CrossRef]
  • 31.Chapple CR. Alpha adrenoceptor antagonists in the year 2000: Is there any thing new? Curr Opin Urol 2001;11:9–16. [CrossRef ]
  • 32.Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999–1004. [CrossRef ]
  • 33.Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273–5. [CrossRef ]
  • 34.Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007;120:370–4. [CrossRef ]
  • 35.Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2009;56:534–41. [CrossRef ]
  • 36.Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72:1061–7. [CrossRef ]
  • 37.Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 2010;29:97–106. [CrossRef ]
  • 38.Barbosa JA, Muracca E, Nakano E, Assalin AR, Cordeiro P, Paranhos M et al. Interactions between lower urinary tract symptoms and cardiovascular risk factors determine distinct patterns of erectile dysfunction: a latent class analysis. J Urol 2013;190:2177–82. [CrossRef ]
  • 39.Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994–1003. [CrossRef ]
  • 40.Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl 2015;17:1022–32. [CrossRef ]
  • 41.Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2016;70:124–33. [CrossRef ]
  • 42.Zhang J, Li X, Yang B, Wu C, Fan Y, Li H. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol 2019;37:143–53. [CrossRef ]
  • 43.Kallidonis P, Adamou C, Kotsiris D, Ntasiotis P, Verze P, Athanasopoulos A; Young Academic Urologists of the European Association of Urology-Endourology Working Party. Combination therapy with alpha-blocker and phosphodiesterase-5 inhibitor for improving lower urinary tract symptoms and erectile dysfunction in comparison with monotherapy: a systematic review and meta-analysis. Eur Urol Focus 2020;6:537–58. [CrossRef ]
  • 44.Elkelany OO, Owen RC, Kim ED. Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Ther Clin Risk Manag 2015;11:507–13. [CrossRef ]
  • 45.Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014;191:727–33. [CrossRef ]
  • 46.Roehrborn CG, Casabé A, Glina S, Sorsaburu S, Henneges C, Viktrup L. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int J Urol 2015;22:582–87. [CrossRef ]
  • 47.Olesovsky C, Kapoor A. Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Ther Adv Urol 2016;8:257–71. [CrossRef ]
  • 48.Watanabe D, Yamashita A, Miura K, Mizushima A. Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. Aging Male 2018;20:1–6. [CrossRef ]
  • 49.Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014;33:17–30. [CrossRef ]
  • 50.Wada N, Iuchi H, Hashizume K, Matsumoto S, Kakizaki H. Urodynamic efficacy and safety of mirabegron add-on treatment with tamsulosin for Japanese male patients with overactive bladder. Low Urin Tract Symptoms 2016;8:171–6. [CrossRef ]
  • 51.Chapple C, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol 2017;10:131–51. [CrossRef ]
  • 52.Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol 2015;193:921–6. [CrossRef ]
  • 53.Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus 2020;6:729–37. [CrossRef ]
  • 54. Yamanishi T, Kaga K, Sakata K, Yokoyama T, Kageyama S, Fuse M, Tokunaga S. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurology and Urodynamics 2020;39:804–12. [CrossRef ]
  • 55.Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010;75:1144–8. [CrossRef ]
  • 56.Maeda T, Kikuchi E, Hasegawa M, Ishioka K, Hagiwara M, Miyazaki Y, et al. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia. Urology 2015;85:1151–5. [CrossRef ]
  • 57.Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L , Karashchuk E, et al. The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin. J Sex Med 2018;15:1579–90. [CrossRef ]
  • 58.Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, open‐label, controlled trial (DIrecT Study). Int J Urol 2017;24:525–31. [CrossRef ]
  • 59.Yamanishi T, Asakura H, Seki N, Tokunaga S. A 52-week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). Low Urin Tract Symptoms 2019;11:115–21. [CrossRef ]
  • 60.Hizli F, Uygur MC. A prospective study of the efficacy of serenoa repens, tamsulosin, and serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol 2007;39:879–86. [CrossRef ]
  • 61. Argirović A, Argirović D. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013;70:1091–96. [CrossRef ]
  • 62.Ryu YW, Lim, SW, Kim JH, Ahn SH, Choi JD. Comparison of tamsulosin plus serenoa repens with tamsulosin in thevtreatment of benign prostatic hyperplasia in Korean men:1-year randomized open label study. Urol Int 2015;94:187–93. [CrossRef ]
  • 63.Boeri L, Capogrosso P, Ventimiglia E, Pederzoli F, Moretti D, Dehòet F, et al. Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone. Sci Rep 2017;7:15179. [CrossRef ]
  • 64. Wang X, Wang X, Li S, Meng Z, Liu T, Zhang X. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One 2014;9:e107593. [CrossRef ]
APA Atan A (2021). Benign prostat hiperplazisinde kombinasyon tedavileri. , 30 - 36. 10.24898/tandro.2021.05945
Chicago Atan Ali Benign prostat hiperplazisinde kombinasyon tedavileri. (2021): 30 - 36. 10.24898/tandro.2021.05945
MLA Atan Ali Benign prostat hiperplazisinde kombinasyon tedavileri. , 2021, ss.30 - 36. 10.24898/tandro.2021.05945
AMA Atan A Benign prostat hiperplazisinde kombinasyon tedavileri. . 2021; 30 - 36. 10.24898/tandro.2021.05945
Vancouver Atan A Benign prostat hiperplazisinde kombinasyon tedavileri. . 2021; 30 - 36. 10.24898/tandro.2021.05945
IEEE Atan A "Benign prostat hiperplazisinde kombinasyon tedavileri." , ss.30 - 36, 2021. 10.24898/tandro.2021.05945
ISNAD Atan, Ali. "Benign prostat hiperplazisinde kombinasyon tedavileri". (2021), 30-36. https://doi.org/10.24898/tandro.2021.05945
APA Atan A (2021). Benign prostat hiperplazisinde kombinasyon tedavileri. Androloji Bülteni, 23(1), 30 - 36. 10.24898/tandro.2021.05945
Chicago Atan Ali Benign prostat hiperplazisinde kombinasyon tedavileri. Androloji Bülteni 23, no.1 (2021): 30 - 36. 10.24898/tandro.2021.05945
MLA Atan Ali Benign prostat hiperplazisinde kombinasyon tedavileri. Androloji Bülteni, vol.23, no.1, 2021, ss.30 - 36. 10.24898/tandro.2021.05945
AMA Atan A Benign prostat hiperplazisinde kombinasyon tedavileri. Androloji Bülteni. 2021; 23(1): 30 - 36. 10.24898/tandro.2021.05945
Vancouver Atan A Benign prostat hiperplazisinde kombinasyon tedavileri. Androloji Bülteni. 2021; 23(1): 30 - 36. 10.24898/tandro.2021.05945
IEEE Atan A "Benign prostat hiperplazisinde kombinasyon tedavileri." Androloji Bülteni, 23, ss.30 - 36, 2021. 10.24898/tandro.2021.05945
ISNAD Atan, Ali. "Benign prostat hiperplazisinde kombinasyon tedavileri". Androloji Bülteni 23/1 (2021), 30-36. https://doi.org/10.24898/tandro.2021.05945
Sayfa Oluşturulma Tarihi
27-04-2024 9:29

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları